The embarrassment of the original innovative drug is also the epitome of the status quo of innovation

Source: dongfang.com on November 19, 2014, as a returned doctor of medicine, Ding Liming achieved great success on the road of entrepreneurship with Kemena However, as an entrepreneur, there are many headache problems in front of him, ranging from new drug approval, market access to medical insurance catalog, and even corporate tax burden Approval is slow, and it takes an average of one and a half years to get a new drug certificate; difficult access to medical insurance: many ordinary people still can't use it; high tax burden is another big pressure for innovative pharmaceutical enterprises (China Economic Weekly, November 18) China has always been regarded as a "big country of generic drugs" in the world According to reports, more than 90% of domestic drugs are generic drugs The output value ratio of innovative drugs and generic drugs in most countries in the world is about 3:1, while that in China is 1:3 It can be said that the current situation of innovation in China's pharmaceutical industry is not optimistic, and it is difficult to see more effective improvement in the future What's more, at present, we can't see the favorable factors that can be expected, and there is still a long way to go to implement the innovation in the pharmaceutical industry Capital has the nature of pursuing profits If the original new drugs can't exceed the income of cost investment, they will lose interest in the original new drugs, so as to achieve "short and smooth" As a result, most of the drugs in the market are unable to obtain patent protection and have corresponding independent property rights Although the sales volume is large, there is no greater profit space Naturally, it will not bring up the pharmaceutical R & D, production and sales enterprises with world influence The situation of "one drug, many imitations" appears repeatedly, the phenomenon of price competition among manufacturers is serious, the profit space of the industry is greatly reduced, even causing losses Judging from the recent revision of pharmaceutical industry events, when pharmaceutical enterprises are in a low-end and vicious competition environment, "control cost" will become illegal behavior and produce "regular inferior drugs" On the contrary, if drug companies have a large number of competitive R & D new drugs, they will inevitably have relative market initiative and greater profit space Therefore, it is imperative to activate the innovation power of the pharmaceutical industry and cultivate China's own R & D enterprises However, why is the reality the opposite? The reason lies in the limitation of rigid system, which leads to great risk of drug innovation, too many uncertain factors and weak innovation willingness of pharmaceutical enterprises For example, due to the long and complex examination and approval process, it will take several years for a new drug to enter the market from project approval and clinical application for approval Once it is listed, it may not be able to enter the medical insurance catalogue and the sales are limited At the same time, there are many deficiencies in the protection of patents in China - the period of patent protection for new drugs, which is not specially stipulated in China, that is, the protection of invention patents 20 The utility model and appearance design are protected for 10 years The patent protection period of the United States, Japan and other countries is also 20 years, but the United States and Japan have implemented the patent compensation period system However, such embarrassment is not only in the field of medicine Although China's economy has achieved great success, the short board of insufficient innovation ability still hasn't been fundamentally changed Some key technologies in key areas are still firmly grasped by foreign countries Although China has become a world factory, they are only big but not strong Before that, some generation processing enterprises only made a few cents to produce a mobile phone, and they had to produce 800 million shirts to replace a Boeing aircraft Innovation is the way out for China in the future However, why the innovation power is not strong and the innovation ability cannot be enhanced all the time? I'm afraid we need to reflect on the environmental factors Activating innovation is a systematic project, which can not be separated from the reform of examination and approval system, the improvement of administrative efficiency, and the support of land, tax, financing and subsidies More importantly, under the guidance of policies, we must reach a consensus on innovation protection and incentives, and really put them into action If even the administrative approval of "quick review and approval" can not be achieved, then other protection measures can only be empty talk When did the original new drug entrepreneurs get less headache and when did the innovation environment get real cultivation